Cargando…

Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019

BACKGROUND: There is paucity of data examining healthcare costs among persons with comorbid diabetes and cardiorenal conditions. OBJECTIVE: To elucidate the longitudinal trends and quantify the incremental healthcare costs associated with the following cardiorenal conditions: atherosclerotic cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Chintal H., Dave, Chintan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703659/
https://www.ncbi.nlm.nih.gov/pubmed/36443803
http://dx.doi.org/10.1186/s13098-022-00957-z
_version_ 1784839901125017600
author Shah, Chintal H.
Dave, Chintan V.
author_facet Shah, Chintal H.
Dave, Chintan V.
author_sort Shah, Chintal H.
collection PubMed
description BACKGROUND: There is paucity of data examining healthcare costs among persons with comorbid diabetes and cardiorenal conditions. OBJECTIVE: To elucidate the longitudinal trends and quantify the incremental healthcare costs associated with the following cardiorenal conditions: atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and kidney disease, among persons with diabetes. METHODS: Medical Expenditure Panel Survey data (2008–2019) were used to identify adults with diabetes and comorbid cardiorenal conditions. Overall, medical and pharmaceutical costs were ascertained (in 2019 US dollars). Analyses were adjusted for 14 variables using a two-part regression model. RESULTS: Among 32,519 adults with diabetes, the mean (standard error [SE]) annual healthcare costs were $13,829 ($213), with medical and prescription components contributing $9301 ($172) and $4528 ($98), respectively. Overall healthcare costs rose by 26.8% from $12,791 (2008–2009) to $16,215 (2018–2019) over the study period, driven by 42.5% and 20.3% increase in pharmaceutical and medical spending, respectively. Similar trends were observed for subgroup of persons with cardiorenal conditions. Compared to their counterparts without cardiorenal conditions and prior to adjustment, persons with ASCVD, HF and kidney disease incurred healthcare costs that were approximately 2.2, 3.3, and 2.7 times greater. After adjustment, comorbid ASCVD, HF and kidney disease were associated with annual excess spending of $8651 (95% CI $7729–$9573), $9373 (95% CI $9010–$9736), and $9995 (95% CI $8781–$11,209), respectively. CONCLUSIONS: Study results are generalizable to non-institutionalized US persons. Healthcare costs associated with the management of diabetes are high—especially among those with comorbid cardiorenal conditions, and have risen in recent years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-022-00957-z.
format Online
Article
Text
id pubmed-9703659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97036592022-11-29 Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019 Shah, Chintal H. Dave, Chintan V. Diabetol Metab Syndr Research BACKGROUND: There is paucity of data examining healthcare costs among persons with comorbid diabetes and cardiorenal conditions. OBJECTIVE: To elucidate the longitudinal trends and quantify the incremental healthcare costs associated with the following cardiorenal conditions: atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and kidney disease, among persons with diabetes. METHODS: Medical Expenditure Panel Survey data (2008–2019) were used to identify adults with diabetes and comorbid cardiorenal conditions. Overall, medical and pharmaceutical costs were ascertained (in 2019 US dollars). Analyses were adjusted for 14 variables using a two-part regression model. RESULTS: Among 32,519 adults with diabetes, the mean (standard error [SE]) annual healthcare costs were $13,829 ($213), with medical and prescription components contributing $9301 ($172) and $4528 ($98), respectively. Overall healthcare costs rose by 26.8% from $12,791 (2008–2009) to $16,215 (2018–2019) over the study period, driven by 42.5% and 20.3% increase in pharmaceutical and medical spending, respectively. Similar trends were observed for subgroup of persons with cardiorenal conditions. Compared to their counterparts without cardiorenal conditions and prior to adjustment, persons with ASCVD, HF and kidney disease incurred healthcare costs that were approximately 2.2, 3.3, and 2.7 times greater. After adjustment, comorbid ASCVD, HF and kidney disease were associated with annual excess spending of $8651 (95% CI $7729–$9573), $9373 (95% CI $9010–$9736), and $9995 (95% CI $8781–$11,209), respectively. CONCLUSIONS: Study results are generalizable to non-institutionalized US persons. Healthcare costs associated with the management of diabetes are high—especially among those with comorbid cardiorenal conditions, and have risen in recent years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-022-00957-z. BioMed Central 2022-11-28 /pmc/articles/PMC9703659/ /pubmed/36443803 http://dx.doi.org/10.1186/s13098-022-00957-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shah, Chintal H.
Dave, Chintan V.
Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
title Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
title_full Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
title_fullStr Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
title_full_unstemmed Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
title_short Healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
title_sort healthcare costs associated with comorbid cardiovascular and renal conditions among persons with diabetes, 2008–2019
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703659/
https://www.ncbi.nlm.nih.gov/pubmed/36443803
http://dx.doi.org/10.1186/s13098-022-00957-z
work_keys_str_mv AT shahchintalh healthcarecostsassociatedwithcomorbidcardiovascularandrenalconditionsamongpersonswithdiabetes20082019
AT davechintanv healthcarecostsassociatedwithcomorbidcardiovascularandrenalconditionsamongpersonswithdiabetes20082019